RxDoctor Payments DataLook up a doctor →

Gregory Allen, MD

Family Medicine · Ponchatoula, LANPI 1952398356

Payments from drug & device makers

$23,241in general payments, 2019–2025

Across 1,312 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$3K
  • Amgen$2K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Pfizer$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$23,07999%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca91$3,891
GSK171$2,833
Amgen(2 entities)111$1,974
AbbVie(2 entities)168$1,936
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC112$1,658
Pfizer93$1,321
Novo Nordisk55$1,189
Lilly USA, LLC62$986
Boehringer Ingelheim69$802
Sunovion Pharmaceuticals Inc.61$702
Bayer29$518
Merck26$414
Astellas Pharma US Inc21$402
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$355
Takeda Pharmaceuticals U.S.A., Inc.21$353
Biohaven Pharmaceuticals, Inc.5$347
Amarin Pharma, Inc.20$303
Sanofi-aventis U.S. LLC21$296
Axsome Therapeutics, Inc.11$268
Johnson & Johnson17$246
E.r. Squibb & Sons, L.L.C.13$207
Antares Pharma, Inc.6$173
Esperion Therapeutics, Inc.9$162
Biohaven Pharmaceutical Holding Company Ltd.3$137
Novartis6$105
Arbor Pharmaceuticals, Inc.7$103
Viatris Specialty LLC4$98
Eisai Inc.6$94
Idorsia Pharmaceuticals US Inc6$91
Teva Pharmaceuticals USA, Inc.6$91
Jazz Pharmaceuticals Inc.5$83
Tolmar, Inc.4$78
Radius Health, Inc.4$76
Abbott3$61
Upsher-smith Laboratories LLC3$59
Otsuka America Pharmaceutical, Inc.3$52
Ironwood Pharmaceuticals, Inc3$51
Exact Sciences3$49
Currax Pharmaceuticals LLC3$47
Daiichi Sankyo Inc.3$43
Ardelyx, Inc.2$42
Phathom Pharmaceuticals, Inc.2$40
Clarus Therapeutics Inc.3$38
Lundbeck LLC2$35
Tris Pharma Inc2$35
Kowa Pharmaceuticals America, Inc.2$33
Paratek Pharmaceuticals, Inc.2$32
Sumitomo Pharma America, Inc.8$28
VBI Vaccine (delaware) Inc.1$26
Xeris Pharmaceuticals, Inc.1$25
Globus Medical1$24
Halozyme Inc1$22
Avanir Pharmaceuticals, Inc.1$20
Philips North America LLC1$19
Alk-abello, Inc1$19
Mimedx Group, Inc.1$18
Neurocrine Biosciences, Inc.1$18
Seqirus USA Inc1$17
Boston Scientific1$17
Azurity Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,241 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$221,364
Medicare patients
440
Services billed
3,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$142,620
Breztri AerosphereBudesonide/Glycopyr/Formoterol149$112,293
MounjaroTirzepatide90$111,560
JardianceEmpagliflozin141$103,487
FarxigaDapagliflozin Propanediol84$83,091
OzempicSemaglutide70$82,442
LinzessLinaclotide111$79,559
ProliaDenosumab44$75,399
XareltoRivaroxaban73$65,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$57,132
XifaxanRifaximin34$50,227
VascepaIcosapent Ethyl98$42,409
EntrestoSacubitril/Valsartan52$42,253
OtezlaApremilast13$33,943
AptiomEslicarbazepine Acetate49$30,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$3,891$195,384233 claims
PfizerEliquis$1,321$142,620183 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$802$129,936171 claims
AbbVieLinzess, Vraylar, Qulipta, Restasis$1,936$129,585159 claims
Lilly USA, LLCMounjaro, Trulicity$986$129,560109 claims
AmgenProlia, Otezla$1,974$109,34257 claims
Novo NordiskOzempic$1,189$82,44270 claims
GSKTrelegy Ellipta, Breo Ellipta$2,833$72,707111 claims
Johnson & JohnsonXarelto$246$65,13573 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,658$50,22734 claims
NovartisEntresto$105$42,25352 claims
MerckJanuvia, Belsomra$414$33,89360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Ponchatoula

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →